These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 5561247)

  • 1. [Evaluation of serum ceruloplasmin levels in prostate diseases: preliminary investigation of the effect of therapeutic estrogens on serum levels of this protein].
    Bélanger L
    Union Med Can; 1971 Aug; 100(8):1554-62. PubMed ID: 5561247
    [No Abstract]   [Full Text] [Related]  

  • 2. [Serum chromogranin A in prostate cancer. Preliminary results].
    Reale MG; Marchei GG; Boccia S; Cristofoletti C; Caporossi E; Marchei M; Izzo P; Marchei P
    Minerva Med; 1999; 90(7-8):221-3. PubMed ID: 10719423
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
    Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
    Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Androgens and the prostate].
    Robel P; Jardin A
    Prog Urol; 1991 Jun; 1(3):476-83. PubMed ID: 1844725
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum sodium and chloride in prostatic hypertrophy and cancer.
    Casey AE; Gilbert FE; Downey EL; Thomason S; Deacy JV
    Ala J Med Sci; 1970 Jan; 7(1):109-10. PubMed ID: 4193657
    [No Abstract]   [Full Text] [Related]  

  • 6. [Monstrous prostatic calculus and a diagnostic error with important consequences].
    Matz M; Schott H
    Z Urol Nephrol; 1976 Jan; 69(1):27-31. PubMed ID: 961109
    [No Abstract]   [Full Text] [Related]  

  • 7. [The prostate and male hormones after 50 years of age].
    de Lignières B; Martin PM
    Ann Med Interne (Paris); 1988; 139(6):405-9. PubMed ID: 3066250
    [No Abstract]   [Full Text] [Related]  

  • 8. Copper and ceruloplasmin status in serum of prostate and colon cancer patients.
    Nayak SB; Bhat VR; Upadhyay D; Udupa SL
    Indian J Physiol Pharmacol; 2003 Jan; 47(1):108-10. PubMed ID: 12708132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA): its clinical value in prostatic disease.
    Dutkiewicz S; Witeska A
    Mater Med Pol; 1994; 26(1):21-4. PubMed ID: 7528864
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute phase reactant proteins in prostatic cancer.
    Ward AM; Cooper EH; Houghton AL
    Br J Urol; 1977 Oct; 49(5):411-8. PubMed ID: 73395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurements of prolactin and androgens in patients with prostatic disease.
    Saroff J; Kirdani RY; Chu TM; Wajsman Z; Murphy GP
    Surg Forum; 1977; 28():568-9. PubMed ID: 83009
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogens and aspects of prostate disease.
    Prezioso D; Denis LJ; Klocker H; Sciarra A; Reis M; Naber K; Lobel B; Pacik D; Griffiths K
    Int J Urol; 2007 Jan; 14(1):1-16. PubMed ID: 17199853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in serum copper and serum ceruloplasmin concentration induced by surgical trauma.
    Hallböök T; Hedelin H
    Acta Chir Scand; 1980; 146(6):371-3. PubMed ID: 7468069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prolactin and cancer of the prostate (III). Changes in plasma prolactin and testosterone after hormone treatment in prostatic cancer].
    Maganto Pavón E; Mateos Torres JA; Mayayo Dehesa T; Allona Almagro A; Boronat Tormo F; Escudero Barrilero A
    Arch Esp Urol; 1982; 35(4):222-33. PubMed ID: 7138091
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease.
    Boddy JL; Gal S; Malone PR; Harris AL; Wainscoat JS
    Clin Cancer Res; 2005 Feb; 11(4):1394-9. PubMed ID: 15746038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen testing. An essential guide to its use and meaning.
    Marks SH
    Adv Nurse Pract; 2001 Apr; 9(4):38-9, 43-4. PubMed ID: 12420434
    [No Abstract]   [Full Text] [Related]  

  • 18. Carcinoma of prostate: the effect of oestrogens on blood viscosity.
    Nandi SR; Knox J
    Br J Clin Pract; 1986 Sep; 40(9):383-5. PubMed ID: 3801264
    [No Abstract]   [Full Text] [Related]  

  • 19. Monocyte tissue factor levels in cancer patients.
    Lwaleed BA; Francis JL; Chisholm M
    Saudi Med J; 2000 Aug; 21(8):722-9. PubMed ID: 11423883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.